As part of our ongoing aim to bring you reports of new developments, we have added a review of the recent SUMMIT study: Tirzepatide for heart failure with preserved ejection fraction and obesity: improved outcomes and insights into underlying mechanisms. The Review examines the main study along with recently published secondary analysis.
Independent commentary has been provided by Associate Professor Adam Nelson a cardiologist and clinical trialist at the Royal Adelaide and Queen Elizabeth Hospitals as well as the University of Adelaide.
Please login below to download this issue (PDF)